论文部分内容阅读
目的观察康莱特注射液联合吉西他滨与顺铂化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效,并探讨其对免疫功能的影响。方法选取2014年4月—2016年4月凉山州第一人民医院收治的晚期NSCLC患者82例,采用随机数字表法分为对照组和观察组,每组41例。对照组患者采用西他滨与顺铂化疗方案,连续治疗4个化疗周期;观察组患者在对照组基础上给予康莱特注射液,连续治疗4个疗程。比较两组患者临床疗效,治疗前后生活质量评分、外周血CD_4~+细胞分数及CD_(25)~+细胞分数,观察两组患者治疗期间毒副作用/不良反应发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。两组患者治疗前精神状况、心理状况、治疗状况、社会关系评分比较,差异无统计学意义(P>0.05);观察组患者治疗后精神状况、心理状况、治疗状况、社会关系评分低于对照组(P<0.05)。两组患者治疗前外周血CD_4~+细胞分数、CD_(25)~+细胞分数比较,差异无统计学意义(P>0.05);观察组患者治疗后外周血CD_4~+细胞分数、CD_(25)~+细胞分数低于对照组(P<0.05)。两组患者治疗期间均未出现明显毒副作用/不良反应。结论康莱特注射液联合吉西他滨与顺铂化疗方案治疗晚期NSCLC的临床疗效确切,可有效提高患者生活质量及免疫功能。
Objective To observe the clinical effect of Kanglaite injection combined with gemcitabine and cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) and to explore its impact on immune function. Methods Eighty-two patients with advanced NSCLC admitted from the First People’s Hospital of Liangshan Prefecture from April 2014 to April 2016 were randomly divided into control group and observation group with 41 cases in each group. Patients in the control group were treated with cisplatin and cisplatin alone for 4 cycles of chemotherapy. Patients in the observation group were given Kanglaite Injection on the basis of the control group for 4 courses of continuous treatment. The clinical efficacy, quality of life before and after treatment, CD_4 ~ + cell fraction and CD_ (25) ~ + cell fraction in the two groups were compared. The side effects and side effects during treatment were observed. Results There was no significant difference in clinical efficacy between the two groups (P> 0.05). There was no significant difference in mental status, psychological status, treatment status and social relationship score between the two groups before treatment (P> 0.05). The mental status, psychological status, treatment status and social relationship score of the patients in the observation group after treatment were lower than those in the control Group (P <0.05). There was no significant difference in CD_4 ~ + cell fraction and CD_ (25) ~ + cell fraction in peripheral blood between the two groups before treatment (P> 0.05) ) ~ + Cell fraction lower than the control group (P <0.05). No significant adverse side effects / adverse reactions occurred in both groups during treatment. Conclusion Kanglaite injection combined with gemcitabine and cisplatin chemotherapy regimen for the treatment of advanced non-small cell lung cancer has the exact clinical efficacy, which can effectively improve patients’ quality of life and immune function.